The Ernest and Helen Scott Haematological Research Institute was established in January 2014 and is located within the University of Leicester. The Institute is directed by Professors Martin Dyer and Simon Wagner.

One of the principal aims of the Institute is to expedite the clinical development and assessment of new precision medicines for the treatment of lymphoid malignancies.

**What we can deliver:**

1. **Pre-clinical assessment and reverse translational studies**
   - Pre-clinical assessment of novel agents alone and in combination, using both *in vitro* and *in vivo* models
   - A large and well-characterized biobank of primary cases, derived cell lines and patient-derived xenograft models
   - Ability to conduct *ex vivo* mechanism based studies of novel targeted therapies across treatment courses

2. **Clinical Trials**
   - Strong links with the Hope Clinical Trials Unit in Leicester specialised in FIM studies
   - With a large catchment population, rapid recruitment to clinical trials is ensured and constantly at high rate
   - A broad clinical trials portfolio encompassing a wide range of novel agents at all stages of clinical development
   - Experienced trials team
   - Strong links with pharmaceutical companies

More information on [http://www2.le.ac.uk/departments/csmm/research/the-ernest-and-helen-scott-haematological-research-institute](http://www2.le.ac.uk/departments/csmm/research/the-ernest-and-helen-scott-haematological-research-institute)

Professor Martin Dyer: mjsd1@le.ac.uk, Professor Simon Wagner: sw227@le.ac.uk

**Recent clinical trial published work**

- EHA2014: A Phase I study of the oral BTK inhibitor ONO-4059 in patients with relapsed/refractory and high risk chronic lymphocytic leukaemia (CLL)
- ASH2014: Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study